VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…
J-A. Sahel (left)_B.Roska (right) J-A. Sahel (left)_B.Roska (right)Basel, Switzerland, June 22, 2023 --In recognition of their pioneering work on restoring…
30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS NetworkBURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) --…
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE…
PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that…
The Company expands technology for patients with obsessive-compulsive disorderMALVERN, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),…
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical…
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of…
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination biweekly regimen showed…
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first…